Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Table 4 Adverse events, hospital admissions and discontinuation rates of patients with genotype 1 hepatitis C virus infection who received 8-wk ledipasvir/sofosbuvir therapy

Adverse events	n (%)
No. adverse event, mean ± SD (Range)	0.5 ± 0.7 (0-6)
Serious adverse events	4 (0.5)
Hospital admissions
Non-cardiac chest pain	2
Drug-induced liver injury	1
Pneumonia	1
Minor adverse events
Fatigue	104 (14)
Headache	98 (13)
Insomnia	35 (5)
Arthralgia/myalgia	29 (4)
Nausea	29 (4)
Cough	15 (2)
Rash	19 (3)
Dizziness	12 (2)
Diarrhea	14 (2)
Pruritus	11 (1)
Irritability/anxiety	10 (1)
Edema	2 (< 0.5)
Discontinuation	4 (0.5)
Drug-induced liver injury	1
Severe rheumatoid arthritis exacerbation	1
Intractable nausea	1
Decreased renal function during treatment (GFR < 30)	1
Death	0

GFR: Glomerular filtration rate.